RGEN Stock Analysis: Repligen | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 7.111m USD | 12M Return: 12.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 147M
EPS Trend: 18.2%
Qual. Beats: 0
Rev. Trend: 86.8%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Repligen Corporation (NASDAQ: RGEN) is a U.S.-based life sciences company headquartered in Waltham, Massachusetts, that develops and commercializes bioprocessing technologies and systems used in the manufacture of biological drugs. Founded in 1981, Repligen sells its products globally across North America, Europe, and Asia Pacific to biopharmaceutical manufacturers, diagnostics companies, contract manufacturing organizations (CMOs), and laboratory researchers.
The companys portfolio spans both upstream and downstream bioprocessing, including hollow fiber consumables, Protein A affinity chromatography resins and pre-packed OPUS columns, filtration systems (such as XCell ATF cell retention devices and KrosFlo tangential flow filtration), and a range of Process Analytical Technology (PAT) tools like PATsmart MAVERICK and the SoloVPE slope spectroscopy system. Repligen also markets products under brands including XCell, TFDF, ProConnex, Spectra/Por, Metenova MixOne, and AVIPure, and maintains a collaboration with Navigo Proteins GmbH to develop affinity ligands.
Repligen operates within the Life Sciences Tools & Services sub-industry, supplying consumables and instruments that support biologic drug development and manufacturing, a segment that has grown alongside the broader rise of monoclonal antibodies and other complex biologic therapies. As a mid-cap company, it sits among specialist vendors that enable biopharma production workflows rather than developing therapeutics directly.
- Protein A resins drive recurring bioprocessing revenue growth
- Cell and gene therapy CDMOs expand filtration product orders
- FDA biologic approvals accelerate bioprocessing capital spending
| Net Income: 41.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.10 > 1.0 |
| NWC/Revenue: 136.0% < 20% (prev 138.6%; Δ -2.54% < -1%) |
| CFO/TA 0.05 > 3% & CFO 134.9m > Net Income 41.5m |
| Net Debt (21.5m) to EBITDA (121.8m): 0.18 < 3 |
| Current Ratio: 9.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.7m) vs 12m ago 0.27% < -2% |
| Gross Margin: 51.05% > 18% (prev 44.25%; Δ 6.80% > 0.5%) |
| Asset Turnover: 26.83% > 50% (prev 23.23%; Δ 3.61% > 0%) |
| Interest Coverage Ratio: 3.50 > 6 (EBIT TTM 77.5m / Interest Expense TTM 22.1m) |
| A: 0.36 (Total Current Assets 1.20b - Total Current Liabilities 132.7m) / Total Assets 2.95b |
| B: 0.16 (Retained Earnings 469.6m / Total Assets 2.95b) |
| C: 0.03 (EBIT TTM 77.5m / Avg Total Assets 2.93b) |
| D: 2.52 (Book Value of Equity 2.11b / Total Liabilities 838.1m) |
| Altman-Z'' = 5.72 = AAA |
| DSRI: 0.86 (Receivables 157.7m/157.0m, Revenue 785.1m/674.0m) |
| GMI: 0.87 (GM 44.25% / 51.05%) |
| AQI: 0.95 (AQ_t 0.50 / AQ_t-1 0.53) |
| SGI: 1.16 (Revenue 785.1m / 674.0m) |
| TATA: -0.03 (NI 41.5m - CFO 134.9m) / TA 2.95b) |
| Beneish M = -3.18 (Cap -4..+1) = AA |
As of July 30, 2026, the stock is trading at USD 141.23 with a total of 1,486,027 shares traded. Over the past week, the price has changed by +0.81%, over one month by +3.09%, over three months by +24.86% and over the past year by +12.71%.
Current recommended Stop Loss: 131.10 (which is 7.2% or 1.2 ATR below the current price).
Repligen has received a consensus analysts rating of 4.26. Therefore, it is recommended to buy RGEN.
- StrongBuy: 10
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 182.1 | 28.9% |
P/E Trailing = 142.4902
P/E Forward = 66.2252
P/S = 9.3152
P/B = 3.5067
P/EG = 2.0594
Revenue TTM = 785.1m USD
EBIT TTM = 77.5m USD
EBITDA TTM = 121.8m USD
Long Term Debt = 542.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 832.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 141.0m
Net Debt = 21.5m USD (calculated: Debt 832.0m - CCE 810.4m)
Enterprise Value = 7.13b USD (7.11b + Debt 832.0m - CCE 810.4m)
Interest Coverage Ratio = 3.50 (Ebit TTM 77.5m / Interest Expense TTM 22.1m)
EV/FCF = 64.38x (Enterprise Value 7.13b / FCF TTM 110.8m)
FCF Yield = 1.55% (FCF TTM 110.8m / Enterprise Value 7.13b)
FCF Margin = 14.11% (FCF TTM 110.8m / Revenue TTM 785.1m)
Net Margin = 5.29% (Net Income TTM 41.5m / Revenue TTM 785.1m)
Gross Margin = 51.05% ((Revenue TTM 785.1m - Cost of Revenue TTM 384.3m) / Revenue TTM)
Gross Margin QoQ = 53.08% (prev 50.70%)
Tobins Q-Ratio = 2.42 (Enterprise Value 7.13b / Total Assets 2.95b)
Interest Expense / Debt = 2.66% (Interest Expense 22.1m / Debt 832.0m)
Taxrate = 20.35% (10.6m / 52.1m)
NOPAT = 61.7m (EBIT 77.5m * (1 - 20.35%))
Current Ratio = 9.05 (Total Current Assets 1.20b / Total Current Liabilities 132.7m)
Debt / Equity = 0.39 (Debt 832.0m / totalStockholderEquity, last quarter 2.11b)
Debt / EBITDA = 0.18 (Net Debt 21.5m / EBITDA 121.8m)
Debt / FCF = 0.19 (Net Debt 21.5m / FCF TTM 110.8m)
Total Stockholder Equity = 2.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.42% (Net Income 41.5m / Total Assets 2.95b)
RoE = 1.98% (Net Income TTM 41.5m / Total Stockholder Equity 2.10b)
RoCE = 2.93% (EBIT 77.5m / Capital Employed (Equity 2.10b + L.T.Debt 542.2m))
RoIC = 2.21% (NOPAT 61.7m / Invested Capital 2.80b)
WACC = 7.89% (E(7.11b)/V(7.94b) * Re(8.56%) + D(832.0m)/V(7.94b) * Rd(2.66%) * (1-Tc(0.20)))
Discount Rate = 8.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 17.01 | Cagr: 0.10%
[DCF] Terminal Value 76.02% ; FCFF base≈108.8m ; Y1≈113.4m ; Y5≈129.4m
[DCF] Fair Price = 40.39 (EV 2.00b - Net Debt 21.5m = Equity 1.98b / Shares 48.9m; r=8.35% [WACC [floored]]; 5y FCF grow 4.56% → 2.50% )
EPS Correlation: 18.24 | EPS CAGR: 5.61% | SUE: 0.66 | # QB: 0
Revenue Correlation: 86.77 | Revenue CAGR: 9.22% | SUE: 0.90 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.47 | Chg30d=+0.11% | Revisions=+0% | Analysts=12
EPS current Year (2026-12-31): EPS=2.06 | Chg30d=+2.67% | Revisions=+40% | GrowthEPS=+20.2% | GrowthRev=+12.0%
EPS next Year (2027-12-31): EPS=2.58 | Chg30d=+1.35% | Revisions=-17% | GrowthEPS=+25.6% | GrowthRev=+15.6%
[Analyst] Revisions Ratio: +10% (up=4, down=3)